At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 147 enrolled
Drug / intervention
A-101 Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.
In Brief
A Phase 3 clinical trial evaluating A-101 Solution for Seborrheic Keratosis. Completed, enrolled 147 participants across 1 site.
Detailed Summary
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedJan 2016
Primary CompletionOct 2016
TodayJul 2026
First PostedJan 28, 2016
Enrollment StartJan 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.4 years ago
Interventions
A-101 Solutiondrug